-+ 0.00%
-+ 0.00%
-+ 0.00%

InflaRx NV to Prioritize Izicopan Development in Hidradenitis Suppurativa and I&I, Plans Workforce Reduction, China PK Bridging Study, and Cost Structure Optimization to Extend Cash Runway to Mid-2027

Reuters·01/08/2026 13:00:25

Please log in to view news